Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.

Hdl Handle:
http://hdl.handle.net/10147/99108
Title:
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.
Authors:
Korpanty, Grzegorz; Smyth, Elizabeth; Sullivan, Laura A; Brekken, Rolf A; Carney, Desmond N
Affiliation:
Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland. greg.korpanty@gmail.com
Citation:
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. 2010, 235 (1):3-9 Exp. Biol. Med. (Maywood)
Journal:
Experimental biology and medicine (Maywood, N.J.)
Issue Date:
Jan-2010
URI:
http://hdl.handle.net/10147/99108
DOI:
10.1258/ebm.2009.009191
PubMed ID:
20404013
Abstract:
Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.
Item Type:
Preprint
Language:
en
MeSH:
Angiogenesis Inhibitors; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptor, Epidermal Growth Factor; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A
ISSN:
1535-3699

Full metadata record

DC FieldValue Language
dc.contributor.authorKorpanty, Grzegorzen
dc.contributor.authorSmyth, Elizabethen
dc.contributor.authorSullivan, Laura Aen
dc.contributor.authorBrekken, Rolf Aen
dc.contributor.authorCarney, Desmond Nen
dc.date.accessioned2010-05-18T13:26:18Z-
dc.date.available2010-05-18T13:26:18Z-
dc.date.issued2010-01-
dc.identifier.citationAntiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. 2010, 235 (1):3-9 Exp. Biol. Med. (Maywood)en
dc.identifier.issn1535-3699-
dc.identifier.pmid20404013-
dc.identifier.doi10.1258/ebm.2009.009191-
dc.identifier.urihttp://hdl.handle.net/10147/99108-
dc.description.abstractLung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.-
dc.language.isoenen
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshNeovascularization, Pathologic-
dc.subject.meshPiperidines-
dc.subject.meshQuinazolines-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshReceptors, Vascular Endothelial Growth Factor-
dc.subject.meshVascular Endothelial Growth Factor A-
dc.titleAntiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.en
dc.typePreprinten
dc.contributor.departmentDepartment of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland. greg.korpanty@gmail.comen
dc.identifier.journalExperimental biology and medicine (Maywood, N.J.)en

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.